Hansa Biopharma AB (publ) (FRA:24H)
3.270
+0.348 (11.91%)
At close: Jan 23, 2026
Hansa Biopharma AB Revenue
Hansa Biopharma AB had revenue of 30.80M SEK in the quarter ending September 30, 2025, a decrease of -36.70%. This brings the company's revenue in the last twelve months to 178.61M, down -5.69% year-over-year. In the year 2024, Hansa Biopharma AB had annual revenue of 171.32M with 27.76% growth.
Revenue (ttm)
178.61M SEK
Revenue Growth
-5.69%
P/S Ratio
22.09
Revenue / Employee
1.34M SEK
Employees
133
Market Cap
356.82M EUR
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 171.32M | 37.22M | 27.76% |
| Dec 31, 2023 | 134.09M | -20.43M | -13.22% |
| Dec 31, 2022 | 154.53M | 120.65M | 356.12% |
| Dec 31, 2021 | 33.88M | 27.78M | 455.56% |
| Dec 31, 2020 | 6.10M | 2.73M | 81.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Allane SE | 827.69M |
| SIMONA Aktiengesellschaft | 586.42M |
| centrotherm international AG | 288.81M |
| ÜSTRA Hannoversche Verkehrsbetriebe Aktiengesellschaft | 171.37M |
| Novabase S.G.P.S. | 130.35M |
| Wild Bunch AG | 68.86M |
| EUWAX Aktiengesellschaft | 41.42M |
| STINAG Stuttgart Invest AG | 28.92M |
Hansa Biopharma AB News
- 6 weeks ago - Hansa Biopharma AB: Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation - Finanz Nachrichten
- 6 weeks ago - Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation - PRNewsWire
- 2 months ago - Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases Transcript - Seeking Alpha
- 2 months ago - Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases - Slideshow - Seeking Alpha
- 3 months ago - Hansa Biopharma AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Hansa Biopharma AB (publ) (HNSBF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Hansa Biopharma AB (HNSBF) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue ... - GuruFocus
- 3 months ago - Q3 2025 Hansa Biopharma AB Earnings Call Transcript - GuruFocus